[Skip to Navigation]
Comment & Response
March 2017

Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema—Reply

Author Affiliations
  • 1Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 2Editor, JAMA Ophthalmology
  • 3Jaeb Center for Health Research, Tampa, Florida
  • 4Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor
  • 5Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor
  • 6College of Engineering, Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor
JAMA Ophthalmol. 2017;135(3):291-292. doi:10.1001/jamaophthalmol.2016.5686

In Reply We thank Messori and Clark et al for their letters. Messori asked us to comment on whether treatment-related adverse events cost more for repackaged (compounded) bevacizumab, which does not have regulatory approval for intravitreous use. He emphasized that the medicolegal aspects of treatment-related adverse events have become increasingly expensive from a malpractice perspective, and he is concerned about isolated clusters of endophthalmitis events that were due to errors in repackaging.

Add or change institution